Direct oral anticoagulants (DOAs): current recent issues

Groupe Français d'Etudes sur l'Hémostase et la Thrombose

Jeudi 18 Janvier 2018   08:30-10:00   351 room
Joint session
08:30 • Pierre Sié
Reversion of DOA with idarucizumab, andexanet and CCP activated or not: which thrombotic risk?
08:50 • Stéphane Zuily
Venous thromboembolic disease and antiphospholipid syndrome: can an DOA be used?
09:10 • Yves Gruel
Thrombosis and heparin-induced thrombocytopenia: DOA, yes or no?
09:30 • Ismail Elalamy
DOA, thrombosis and cancer: where do we stand?